top of page

Advancing metabolic
cancer medicine

RS Oncology is an innovative biotechnology company leading scientific discoveries and global collaborations to improve the lives of patients with rare and aggressive cancers. 

Doctor and Patient

A Translational Phase 1/2 Dose-Escalation and Expansion Study to Determine Safety, Tolerability, and Recommended Phase 2 Dose of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma.

science grayscale-danshot.png
Innovative scientific discoveries along with a large body of peer reviewed research suggests our mechanism of action is fundamental for all cancer growth.

Proud to support ITONF global education
A webinar from the International Thoracic Oncology Nursing Forum 

Foundations in Mesothelioma Nursing - An Update 

Register Here to view the entire ITONF webinar and hear the latest updates in Mesothelioma with many guest speakers including our lead PI for the Glasgow MITOPE study,  Kevin Blyth. Kevin is a Professor of Respiratory Medicine, Institute of Cancer Sciences, University of Glasgow & Honorary Consultant in Respiratory Medicine. Kevin leads the Glasgow Pleural Disease Unit and is an NRS Senior Research Fellow as well as running a translational research program focused on pleural disease and thoracic malignancy. 

bottom of page